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For many years now, pathologists and melanoma biologists
and immunologists have worried and wondered about the
small number of individuals who are diagnosed with mel-
anoma with a Breslow thickness less than 0.76 mm who
develop metastases and die from melanoma. Clues have
been sparse.
Recent research has focused on predictors of sentinel
lymph node positivity (e.g., Sondak et al, 2004). But Carlson
et al (2003) report that one-third of patients diagnosed with
melanoma present without previous regional lymph node
metastases.
In this issue of the Journal, Giese et al have provided
evidence of the utility of quantifying melanoma micro-
metastases in sentinel lymph nodes using real-time RT-PCR
to assess expression of Melan-A and tyrosinase. The pa-
tients who are negative by RT-PCR and have negative sen-
tinel node histology appear to have 100% recurrence-free
survival. This is an important clinical finding as these pa-
tients may be therefore treated less aggressively than those
who have evidence of lymph node metastases or micro-
metastases. Both patients and oncologists may find this to
be a relief.
On the other hand, what is the utility of this finding for the
34% of individuals (39/116) who had negative histology of
the sentinel lymph node but who had positive RT-PCR re-
sults, only 10% (n¼ 4) of whom had a recurrence of me-
lanoma? The answer to this question lies in the hands of the
biologists and in the long-term follow-up of this and other
similar groups of patients. Although the mean Breslow
thickness of individuals in this study who had positive RT-
PCR and negative histology of the lymph node was 1.2 mm,
it was not different from those with negative histology and
negative RT-PCR (p¼ 0.96), with 100% disease-free recur-
rence. In this instance, Breslow thickness, our most sensi-
tive and robust indicator of disease progression, does not
discriminate. Furthermore, 10% of the patients with nega-
tive histology and positive RT-PCR had a recurrence over a
29 month period. Additional study of this particular group of
subjects, although a small number, may yield more clues to
the biology of melanoma progression.
The critical importance of obtaining accurate information
about staging for melanoma for clinical treatment is clear to
oncologists. But it is also extremely important for epidemi-
ologists and biologists who wish to uncover more accurate
predictive factors than are currently recognized. The current
level of misclassification of individuals diagnosed with
melanoma who will progress and those who will not may
prevent us from identifying critical risk factors that are
associated with progression. If epidemiologists and biolo-
gists can develop more specific and sensitive risk factor
information, then effective interventions to prevent progres-
sion can be developed. But clearly, without such informa-
tion, the efficacy of preventive and therapeutic interventions
is likely to be poor.
Although the utility of RT-PCR is not perfect, this is one
development that may help reduce misclassification of dis-
ease status, and thus it deserves attention, further follow-
up, and development.
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